Quotidian Technical Highlights on Selected Biotech Stocks -- Advaxis, Grifols, Juno Therapeutics, and Lexicon Pharma

Monday, November 27, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, November 27, 2017 /PRNewswire/ --

In keeping with the commitment to dynamically provide members with timely

information WallStEquities.com has issued free tailored Stock Review on ADXS, GRFS, JUNO, and LXRX which is a click away at http://www.wallstequities.com/registration. For today, WallStEquities.com concentrates on the Biotechnology industry, which
consists of companies that are engaged in the research and development of new drugs, medical devices, and procedures. Equities under evaluation this morning are: Advaxis Inc. (NASDAQ: ADXS), Grifols S.A. (NASDAQ: GRFS), Juno Therapeutics Inc. (NASDAQ: JUNO), and Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX). Wall St. Equities has a wide array of free research reports which include today's stock picks, register now to access them at:

http://www.wallstequities.com/registration

Advaxis 

Princeton, New Jersey-based Advaxis Inc.'s shares recorded a trading volume of 257,715 shares last Friday. The stock finished the trading session 3.18% lower at $3.04. The Company's shares are trading below their 50-day moving average by 20.86%. Furthermore, shares of Advaxis, which focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the US, have a Relative Strength Index (RSI) of 39.12.

On November 01st, 2017, Advaxis has received approval for a $4.8 million tax credit from the New Jersey Economic Development Authority's New Jersey Technology Business Tax Certificate Transfer program. The Company anticipates that it will be able to transfer this credit and receive $4.5 million in cash by the end of 2017. Follow the link below to your free research report on ADXS at:

http://www.wallstequities.com/registration/?symbol=ADXS

Grifols 

On Friday, Barcelona, Spain headquartered Grifols S.A.'s stock ended the session 0.35% higher at $23.12. A total volume of 185,497 shares was traded. The Company's shares have gained 8.44% in the last one month, 12.84% over the previous three months, and 43.87% on an YTD basis. The stock is trading 5.28% above its 50-day moving average and 12.60% above its 200-day moving average. Moreover, shares of Grifols, which develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the US, Canada, and internationally, have an RSI of 56.18.

On October 31st, 2017, research firm Citigroup initiated a 'Buy' rating on the Company's stock. The free technical report on GRFS can be accessed at:

http://www.wallstequities.com/registration/?symbol=GRFS

Juno Therapeutics 

Seattle, Washington headquartered Juno Therapeutics Inc.'s stock ended the day 4.18% higher at $62.85 with a total trading volume of 1.27 million shares. The Company's shares have skyrocketed 45.96% in the last month, 104.52% over the previous three months, and 233.42% on an YTD basis. The stock is trading 30.84% and 96.95% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Juno Therapeutics, which engages in developing cell-based cancer immunotherapies, have an RSI of 72.89.

On November 02nd, 2017, research firm SunTrust upgraded the Company's stock rating from 'Hold' to 'Buy'.

On November 06th, 2017, Juno Therapeutics announced that it will present at the Evercore ISI Biopharma Catalyst / Deep Dive Conference on November 29th, 2017, at 8:45 a.m. ET. The presentation, which will feature a business overview and update by Steve Harr, CFO and Head of Corporate Development, will be webcast and accessible under the Investor Relations page of the Company's website. Sign up for free on Wall St. Equities and claim the latest report on JUNO at:

http://www.wallstequities.com/registration/?symbol=JUNO

Lexicon Pharmaceuticals 

Shares in The Woodlands, Texas headquartered Lexicon Pharmaceuticals Inc. recorded a trading volume of 337,670 shares. The stock ended Friday's session flat at $9.75. The Company's shares are trading below their 50-day moving average by 11.45%. Furthermore, shares of Lexicon Pharma, which focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases, have an RSI of 43.37.

On November 08th, 2017, Lexicon Pharma reported financial results for the three months ended September 30th, 2017. Revenues for Q3 2017 decreased to $26.9 million; R&D expenses decreased to $39.1 million; selling, general and administrative expenses increased to $16.7 million; and net loss was $30.7 million. As of September 30th, 2017, the Company had $196.8 million in cash and investments. See the free research coverage on LXRX at:

http://www.wallstequities.com/registration/?symbol=LXRX

--

Wall St. Equities: 

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY 

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

https://wallstequities.com/legal-disclaimer/

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +21-32-044-483 Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Wall St. Equities



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store